yg1699
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 13, 2019 (NCT03953092)
Timeline
Indications
Mechanism of action
- Sodium/glucose cotransporter 2INHIBITOR
SLC5A2 inhibitor
- SGLT1 proteinINHIBITOR
SLC5A1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06648876 | Phase 1 | Oct 31, 2024 | Jiao Tong University |
| NCT05089617 | Phase 1 | Nov 30, 2021 | Youngene Therapeutics Inc., Ltd. |
| NCT04956263 | Phase 2 | Jul 1, 2021 | ProSciento, Inc., Youngene Therapeutics Inc., Ltd. |
| NCT03953092 | Phase 1 | May 13, 2019 | Youngene Therapeutics Inc., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Youngene Therapeutics Inc., Ltd. | For profit | 3 | 3 | 2 | 2019 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| ProSciento, Inc. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1